Prognia
Drug Database
🇪🇺EU · EMAAuthorisedATC: A10AB04

Bysumlog(insulin lispro)

Diabetes Mellitus

Marketing Authorisation Holder: Gan & Lee Pharmaceuticals Europe GmbH

EMA Authorisation: 06/05/2026

INN: insulin lispro

Indication

For the treatment of adults and children with diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. Bysumlog is also indicated for the initial stabilisation of diabetes mellitus.

Official EMA Resources

View on EMA (ema.europa.eu)

AI Drug & Interaction Analysis

Free account required

Ask Prognia AI about Bysumlog — dosing recommendations, drug interactions, and current guideline evidence from ESC, EMA, NICE and more.

Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.